New Page 13





The EkoSonic® Endovascular System now with MACH4e

EkoSonic Endovascular DeviceEKOS set the standard for safety and completeness in dissolving clots with its first generation of ultrasound thrombolytic technology.

It raised the bar with MACH4. And now, EKOS scientists have refined the performance yet again with MACH4e; up to 40% faster
1 than MACH4.

With no evidence of thrombus breakage
2. And no hemolysis3. Less time to complete dissolution means a lower lytic drug dosage.
And that means an even lower risk of complications.

EkoSonic Endovascular SystemA preferred alternative to current therapies

EkoSonic acoustic energy conditions clot by thinning fibrin, increasing porosity and creating a pressure gradient which transports clot dissolving drug deep inside the occluding thrombus.

  • Penetrates thrombus, in difficult–to-reach places, such as behind valves4
  • Uses 50 - 70% less lytic drug4
  • No thrombus fracture or breakage2, reducing the risk of distal embolism
  • Exposes thrombus to greater drug uptake5
  • Captures drug within thrombus5
  • No damage to valves3 or the vascular wall
  • No hemolysis3. Does not fracture red blood cells, so there is no adenosine release and no additional compromise to renal function
  • Higher level of vessel patency, removes the thrombus more completely, possibly reducing the risk of Post-Thrombotic Syndrome (PTS)
  • Shortest physician lab time

Intended Use

Rapid Pulse ModulationThe EkoSonic Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. Contraindications* Not designed for peripheral vasculature dilation purposes.* This system is contraindicated when, in the medical judgment of the physician, such procedure may compromise the patient’s condition.

« Back »


Peripheral Vasculature: Both the EkoSonic Endovascular System and the EkoSonic SV Endovascular Systems are intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, in the peripheral vasculature.

« Back »

  1. EKOS in vitro data on file
  2. Braaten, J., Goss, R., Francis, C. “Ultrasound Reversibly Disaggregates Fibrin Fibers.” Thromb Haemost 78 (1997) 1063-8.4.
  3. Soltani, A., et al “Absence of biological damage from prolonged exposure to intravascular ultrasound.” Ultrasonics 46 (2007) 60-67
  4. Parikh, S., et al. Ultrasound-Accelerated Thrombolysis for the Treatment of Deep Vein Thrombosis: Initial Clinical Experience. Journal of Vascular and
    Interventional Radiology, April, 2008, 19:4, pp521-528.1
  5. Francis, CW. et al. “Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots.” Ultrasound in Medicine and Biology, 21.3 (1995): 419-424
  6. Soltani A, Volz KR, Hansmann DR. “Effect of modulated ultrasound parameters on ultrasound-induced thrombolysis”. Phys Med Biol. 2008. Phys Med Biol, 2008

« Back »

© 2014 EKOS Corporation, a BTG International group company.  All Rights Reserved.  Privacy Policy